Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database

Sponsor
Novartis
Study ID
NCT06600009
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab — DRUG
    Patients had received secukinumab per their dosing regimens prior to this observational study.
  • Adalimumab — DRUG
    Patients had received adalimumab per their dosing regimens prior to this observational study.

Study Details

This study was a retrospective non-interventional cohort study with secondary use of data from the Medical Data Vision (MDV) hospital-based database. The study setting was defined as follows: * The inclusion period covered 01 February 2015 to 30 September 2020. * The study period covered 01 August 2014 to 30 September 2021 inclusive. * The index date was defined as the date of the first prescription of secukinumab or adalimumab within the inclusion period. * The pre-index period was defined as the 6-month period before the index date (exclusive). * Patients were followed until death, discontinuation of treatments of interest or end of the study period, whichever occurred first.

Key Dates

Start date
Oct 17, 2022
Status verified
Sep 2024
Primary completion
Aug 21, 2023
Completion
Sep 15, 2023

Study Design

Enrollment
534 participants (actual)

Arms

  • Arm: Secukinumab
    Patients had received secukinumab treatment.
  • Arm: Adalimumab
    Patients had received adalimumab treatment.

Primary Outcome Measure

Number of Patients with Persistence of Secukinumab Treatment at One Year [ Time Frame: 1 year ]

Related Studies